Amgen
3 articles
Industry NewsAmgenBioSpace
Amgen Starts a MariTide Autoinjector Phase 3 as Tolerability Becomes the Test
- Amgen has begun another Phase 3 trial of home self-administration of subcutaneous MariTide with an autoinjector; ClinicalTrials.gov lists primary completion in June 2027.
- The MARITIME programme has 10 trials, two more are due to start this year, and the first Phase 3 data are expected in 2027.
- Analysts are focused on tolerability rather than weight loss; R&D chief Jay Bradner said a conventional single-chamber handheld device is planned.
Amgen's pitch is dosing as rarely as four times a year, which would separate MariTide from Lilly's and Novo's weekly products, but that only matters if dose escalation is tolerable. The device study is the quiet commercial step: using a conventional autoinjector reduces launch risk if the pivotal data land. Both BMO and Truist describe differentiation as unproven, so the first GI-event data from Phase 3 is the real readout.
Industry NewsAmgenEndpoints News
Amgen's Imdelltra plus Imfinzi cuts death risk 58% in first-line maintenance SCLC
- Amgen presented Phase 3 data at ESMO 2026 for Imdelltra plus AstraZeneca's Imfinzi in first-line maintenance small cell lung cancer.
- The combination reduced the risk of death by 58% versus Imfinzi alone, per Endpoints News.
- A September topline release had reported a statistically significant overall survival gain in the DeLLphi-305 study, which randomized 563 patients.
A 58% cut in death risk against Imfinzi alone, in a 563-patient trial, makes tarlatamab plus durvalumab a credible new first-line maintenance standard in SCLC, a setting with few advances. Pairing with AstraZeneca's PD-L1 incumbent also moves Imdelltra from later-line use toward earlier lines, where its commercial ceiling is far higher. Tolerability and the exact survival figures will decide how fast adoption follows.
Industry NewsAmgenEndpoints News
Amgen's Dazodalibep Hits Primary Endpoint in Phase 3 Sjögren's Disease Trial
- Dazodalibep is a CD40 ligand (CD40L) antagonist fusion protein that blocks a key costimulatory signal between T cells, B cells and antigen-presenting cells implicated in Sjögren's disease.
- The Phase 3 OASIZ 301 trial randomized about 621 adults with moderate-to-severe systemic Sjögren's disease (ESSDAI ≥5) to dazodalibep or placebo.
- The study met its primary endpoint, showing a statistically significant and clinically meaningful reduction in ESSDAI disease-activity scores at Week 48, with benefit emerging as early as Week 4.
- No imbalance in blood clots or opportunistic infections was reported, a closely watched safety signal for this drug class; a second Phase 3 trial, OASIZ 303, in patients with lower systemic disease activity is due to complete in Q4 2026.
No imbalance in blood clots or infections is the headline that matters most: CD40L antagonists carry a long history of thromboembolic failures, so this clean safety data de-risks the whole mechanism, not just Amgen's asset. It also finally validates the $27.8B Horizon buy, giving Amgen the first credible disease-modifying candidate in a zero-approved-therapy indication—with a second Phase 3 in a milder segment positioning it to own both ends of the severity spectrum.